

VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being transmitted with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on April 9, 1999.

Melissa Fairless

Signature

LUD-5330.3 DIV (991357)

645



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Zimmerman, et al.
Serial No. : 09/265,606
Filed : 3/10/99
For : Protein Containing Portions of FAP α and Other Proteins
Group Art Unit : Unknown
Examiner : Unknown

April 9, 1999

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

LETTER

The Notice of April 1, 1999, a copy of which is attached, indicated that, with respect to the above referenced application:

- (i) A copy of the "Sequence Listing",
- (ii) An initial or substitute computer readable form (CRF) copy of the sequence listing, and
- (iii) A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, were required.

Applicants believe that these requirements are not proper, for the following reasons.


The subject application is a divisional of Serial No. 08/940,391. Pursuant to 37 C.F.R. §1.821(e), applicants are entitled to have CRF of sequence information transferred from a parent application; if a proper letter requesting this is filed. Applicants did file such a letter. A copy is attached, as is a copy of applicants' return receipt postcard, noting the item as Number 5. Note that this letter also satisfies the requisites of "(iii)," supra, via the second paragraph.

Further, a paper copy of the sequence listing was also submitted. Please see item "5" of the return receipt postcard.


In view of the foregoing, it is believed that the Notice should be vacated.

Respectfully submitted,

FULBRIGHT & JAWORSKI, LLP

By 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000



CASE # LUD5330 3

Serial No. Q

DATE MAILED: 3/10/99

DATE DUE:

EXP MAIL # EI 605139 215 US

The stamp of the Patent Office herein may be taken as acknowledgement by PTO
of receipt, on the date stamped, of the following: jc530 U.S. 09/265606

- 1 See Trans. (dup) 
2 Utility Patent App Trans (dup) ^{3/18/99}
3 Check 9160 7. Deed (copy)
4 Dream Amst 8. Assignment (copy)
5 Letter § 1.821(e) & seq. listing
6 Copy of 4 from 9160 9. Postcard

VIA EXPRESS MAIL

press Mail" mailing label
ber E160513921US
of Deposit March 10, 1999 •
eby certify that this paper or fee is being deposited with the United States
al Service "Express Mail Post Office to Addressee" service under CFR
on the date indicated above, and is addressed to the Assistant
missioner for Patents Trademarks, BOX PCT Washington, D.C. 20231
FULBRIGHT & JAWORSKI L.L.P.

LUD-5330.3 DIV



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rainer Zimmerman et al.
Serial No. : Divisional of 08/940,391
Filed : Concurrently herewith
For : ISOLATED DIMERIC FIBROBLAST ACTIVATION
PROTEIN ALPHA, AND USES THEREOF
Group Art Unit : 1645
Examiner : M. Navarro

March 10, 1999

Hon. Commissioner of Patents
and Trademarks
Washington D.C. 20231

LETTER IN ACCORDANCE WITH 37 C.F.R. § 1.821(e)

Sir:

Applicants hereby request that the CRF of sequence information sent to the USPTO in Serial No. 08/619,280, the grandparent of this application, be transferred to this divisional application. Please use the CRF filed on May 5, 1997. Paper copy of the information from the CRF is submitted as part of the accompanying preliminary amendment.

The undersigned hereby declares that, to the best of his knowledge, the information on the CRF of May 5 is identical to the paper submitted herewith, and both are identical to the sequence information in the specification as filed.

Respectfully submitted,
FULBRIGHT & JAWORSKI, L.L.P.

By

Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000

556129.1




UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

10731357

SEARCHED
SERIALIZED
INDEXED



DATE MAILED:

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):


- 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. OTHER: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123.
- For CRF submission help, call (703) 308-4212.
- For Patentin software help, call (703) 308-6856.


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rainer Zimmermann et al.
Serial No. : Divisional of Serial No. 08/619,280
Filed : Concurrently herewith
For : ISOLATED DIMERIC FIBROBLAST ACTIVATION PROTEIN ALPHA, AND USES THEREOF
Art Unit : 1818
Examiner : M. Allen

October 1, 1997

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

LETTER IN ACCORDANCE WITH
37 C.F.R. § 1.821(e)

Sir:

Applicants hereby request that the CRF of sequence information sent to the USPTO in Serial No. 08/619,280, the parent of this application, be transferred to this divisional application. Please use the CRF filed on May 5, 1997. Paper copy of the information from the CRF is submitted as part of the accompanying preliminary amendment.

The undersigned hereby declares that, to the best of his knowledge, the information on the CRF of May 5 is identical to the paper submitted herewith, and both are identical to the

information submitted in 08/619,280. No new matter has been presented.

Respectfully submitted,

FELFE & LYNCH

By 
Norman D. Hanson
Reg. No. 30,946

805 Third Avenue
New York, New York 10022
(212) 688-9200

NOTARIZATION FORM COVER SHEET
PATENTS ONLYU.S. GOVERNMENT PRINTING OFFICE
U. S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings: ☐ ☐ ☐ ▼

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(es):

Rainer Zimmermann
 John E. Park
 Wolfgang Rettig

Additional name(s) of conveying party(es) attached? Yes No

3. Nature of conveyance:

- | | |
|--|---|
| <input checked="" type="checkbox"/> Assignment | <input type="checkbox"/> Merger |
| <input type="checkbox"/> Security Agreement | <input type="checkbox"/> Change of Name |
| <input type="checkbox"/> Other _____ | |

Execution Date: June 17 & 18, 1996

2. Name and address of receiving party(es):

Name: Boehringer Ingelheim International

Internal Address: _____

Street Address: D-55216 Ingelheim am Rhein

Federal Republic of Germany

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

08/619,280

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Norman D. Hanson

Internal Address: FELFE & LYNCH

Street Address: 805 Third Avenue

City: New York State: NY ZIP: 10022

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$ 40.00

 Enclosed Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Norman D. Hanson

Name of Person Signing

Signature

June 25, 1996

Date

Total number of pages comprising cover sheet

2

OMB No. 0651-001 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
 Box Assignments
 Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

WHEREAS the undersigned (hereinafter collectively, "ASSIGNOR") have invented certain new and useful improvements in,

ISOLATED DIMERIC FIBROBLAST ACTIVATION PROTEIN ALPHA, AND USES THEREOF

(the "INVENTION") for which an application for United States Letters Patent was filed on March 18, 1996, and assigned Serial No. 08/619,280,

WHEREAS Boehringer Ingelheim International GmbH
D-55216 Ingelheim am Rhein
Federal Republic of Germany

a German corporation (hereinafter "ASSIGNEE") is desirous of acquiring the entire right, title and interest in same:

Now, therefore, in consideration of the sum of one dollar (\$1.00), the receipt whereof is hereby acknowledged, and other good and valuable consideration, the said ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the full and exclusive right to the INVENTION anywhere in the world, the entire right, title and interest in and to any U.S. patent application and any U.S. patent issuing thereon covering the INVENTION, and all corresponding foreign patent applications and patents issuing thereon anywhere in the world. ASSIGNOR will execute all documents deemed necessary by ASSIGNEE to confirm title in ASSIGNEE.

Said ASSIGNOR hereby authorizes and requests that U.S. Letters Patent issue to said ASSIGNEE, as the assignee of the entire right, title, and interest in and to the same, for the sole use and for the use of its successors, legal representatives, and assigns, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held by said ASSIGNOR had this assignment and sale not been made.

Witness, the hand and seal of the ASSIGNOR on the date(s) indicated.

Date(s)

June 12, 1996
Date

June 18, 1996
Date

June 18, 1996
Date

Signature(s)

Rainer Zimmermann
Rainer Zimmermann

JEP
John E. Park

Wolfgang Rettig
Wolfgang Rettig

ASSIGNMENT

WHEREAS the undersigned [hereinafter (collectively) "ASSIGNOR"] have invented certain new and useful improvements in

**ISOLATED DIMERIC FIBROBLAST ACTIVATION
PROTEIN ALPHA, AND USES THEREOF**

(the "INVENTION") for which an application for United States Letters Patent was filed on March 18, 1996, and assigned Serial No. 08/619,280,

WHEREAS Ludwig Institute for Cancer Research
 1345 Avenue of the Americas
 New York, New York 10105

a Swiss, not-for-profit corporation (hereinafter "ASSIGNEE") is desirous of acquiring the entire right, title and interest in same:

Now, therefore, in consideration of the sum of one dollar (\$1.00), the receipt whereof is hereby acknowledged, and other good and valuable consideration, the said ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE, the full and exclusive right to the INVENTION anywhere in the world, the entire right, title and interest in and to any U.S. patent application and any U.S. patent issuing thereon covering the INVENTION, and all corresponding foreign patent applications and patents issuing thereon anywhere in the world. ASSIGNOR will execute all documents deemed necessary by ASSIGNEE to confirm title in ASSIGNEE.

Said ASSIGNOR hereby authorizes and requests that U.S. Letters Patent issue to said ASSIGNEE, as the assignee of the entire right, title, and interest in and to the same, for the sole use and for the use of its successors, legal representatives, and assigns, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held by said ASSIGNOR had this assignment and sale not been made.

Witness, the hand and seal of the ASSIGNOR on the date(s) indicated.

Date(s)

Signature(s)

April 2, 1996

Date

Lloyd J. Old

information submitted in 08/619,280. No new matter has been presented.

Respectfully submitted,

FELFE & LYNCH

By Norman D.

Norman D. Hanson
Reg. No. 30,946

805 Third Avenue
New York, New York 10022
(212) 688-9200